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Abstract
Proton pump inhibitor (PPI) therapy is commonly used outside of Food and Drug Administration indication for a
broad range of conditions such as extra-esophageal reflux and PPI-responsive esophageal eosinophilia. While this
may be appropriate in some scenarios, it has also resulted in widespread inappropriate PPI use. At the same time,
data suggesting adverse effects of long-term PPI therapy are multiplying, albeit mainly from low quality studies.
The systematic review by Scarpignato et al. (BMC Med 14:179, 2016) addresses this dilemma with a comprehensive
analysis of the risks and benefits of PPI use. The authors concluded that, while PPIs are highly efficacious in erosive
acid-peptic disorders, efficacy is not equaled in other conditions. In some instances, they found no supportive
evidence of benefit. With respect to side effects, they indicated that the questionable harms associated with PPI
therapy do not outweigh the benefits afforded by appropriate PPI use. However, inappropriate PPI use results in
increased healthcare costs and unnecessary exposure to potential adverse effects. Ideally, PPI therapy should be
personalized, based on indication, effectiveness, patient preference, and risk assessment.
Please see related article: http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0718-z.
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Background
Proton pump inhibitors (PPIs) have revolutionized the
medical approach to upper gastrointestinal disorders.
Initially developed as a treatment for reflux esophagitis,
these potent inhibitors of gastric acid secretion have
subsequently proven effective for a broad range of syn-
dromes known (or suspected) to be attributable to acid
reflux, acid secretion, or acid hypersecretion. Combined
with seemingly excellent safety and tolerance, these
broadened indications triggered an exponential increase
in PPI use (and consequently cost) worldwide [1, 2].
Furthermore, PPIs have become a victim of their own
success. Not only are they now often prescribed for syn-
dromes of dubious merit (“silent reflux”), but an almost
cultish faith in potent acid suppression as a treatment
for all that ails the human race has led to progressive
escalation of PPI dosage and potency. Indeed, a
vocabulary has emerged around the concept of “PPI fail-
ure”, often ignoring the possibility that the condition in
question had no relationship to gastric acid secretion in
the first place. Consequently, it is no surprise that, in
less than 30 years, PPIs have evolved from wonder drugs
to a major healthcare epidemic. Coupled with this has
been unprecedented scrutiny of the safety of chronic PPI
use; it is in this background that Scarpignato et al. [3]
author a position paper on “Effective and safe proton
pump inhibitor therapy in acid-related diseases”.
Use of PPIs
Coincident with PPI usage, the literature surrounding
PPI safety and efficacy is growing exponentially, making
it difficult to delineate an evidence-based guideline on
their use. In the study by Scarpignato et al. [3], commit-
tees on behalf of three Italian scientific societies collabo-
rated with impressive panels of expert international
reviewers to address 13 clinical scenarios in which un-
certainty exists about how to prescribe PPIs and where
drug misuse is common. They performed a systematic
literature review inclusive of almost 500 papers and
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present a narrative review of the safety and appropriate-
ness of PPI therapy in each scenario. Table 1 summarizes
the key messages regarding appropriate PPI use in the
13 scenarios, organized into those appropriate for long-
term or short-term PPI use, or not at all. Examining this
compendium, one is immediately struck by the fact that
the table includes many usages for which there are no
Food and Drug Administration (FDA) indications.
Apparently, the world literature provides ample evidence
for the efficacy of PPIs outside of FDA indications.
For the current FDA indications for PPI use (indicated
in Table 1, with some liberties taken) there is little rea-
son to quibble about their appropriateness. It is when
the recommendations go beyond FDA recommendations
and in the gray areas where there is great potential over-
use (and conversely, over-regulation), these include
eosinophilic esophagitis, non-erosive reflux disease, che-
moprevention in Barrett’s esophagus, dyspepsia, and
extra-esophageal reflux. Not surprisingly, the evidence
supporting PPI use in these indications is generally
weak. However, saying that the evidence is weak is not
the same as stating that it should not be done. Rather, it
becomes incumbent on the practitioner to establish the
effectiveness of the PPI, or the out-of-indication PPI
dose, for the particular patient. In the case of
eosinophilic esophagitis, long-term PPI use requires
endoscopic/histopathologic verification that PPI use
cleared mucosal eosinophilia. In the case of non-erosive
reflux disease it means coupling PPI therapy with weight
management and lifestyle modification with the ultimate
goal of tapering PPI therapy to the lowest effective dose.
Prior relevant studies have shown that PPI dosage can
be successfully reduced in the majority of such patients
and entirely discontinued in nearly 20% [2].
The role of PPI therapy for managing extra-esophageal
symptoms that are potentially from gastroesophageal re-
flux is even more perplexing. Scarpignato et al. [3] high-
light the paucity of high-quality data regarding PPI
therapy for non-cardiac chest pain, laryngeal complaints,
asthma, dental erosions, and chronic cough. Paradoxic-
ally, this has led to the widespread practice of treating
these conditions with high doses of PPIs for extended
periods of time. Furthermore, with no specified alterna-
tive management strategy, this frequently leads to long-
term high-dose PPI usage in these conditions regardless
of effectiveness [4, 5]. More than any, these patients
benefit from further physiological investigation (manom-
etry, reflux monitoring) to either implicate PPI-
Table 1 Summary of the conclusions by Scarpignato et al. [3] regarding the appropriateness of proton pump inhibitor (PPI) therapy
in 13 clinical scenarios of uncertainty and common misuse
Reason for use
Long-term PPI therapy appropriate • Barrett’s esophagus
• Healing and maintenance of healed Los Angeles grade C or D erosive esophagitisa
• PPI-responsive esophageal eosinophilia
• Idiopathic (H. pylori and NSAID/aspirin negative) peptic ulcer disease
• Zollinger–Ellison diseasea,b
• PPI-responsive GERD/non-erosive reflux diseasea,c
• Long-term non-selective NSAID users at high-risk for upper GI complications or long-
term cox-2 inhibitor users with a prior episode of GI bleedinga
• Anti-platelet therapy in patients at high-risk for upper GI complications (age > 65 years
or concomitant use of corticosteroids or anticoagulants or history of peptic ulcer disease)
• Steatorrhea refractory to enzyme replacement therapy in chronic pancreatitis
Short-term PPI therapy appropriate (4- to 12-week course) • Healing of Los Angeles grade A or B erosive esophagitisa
• Eosinophilic esophagitis
• H. pylori eradication (in combination with antibiotics)a,d
• Stress ulcer prophylaxis in high-risk patients (i.e., critically ill patients with respiratory
failure or coagulopathy)
• Functional dyspepsia
• Treatment and maintenance of peptic ulcer diseasea
• Prior to endoscopy for acute upper GI bleeding
• Following endoscopic treatment of a high-risk ulcer GI bleed
PPI use not appropriate • Corticosteroid users without concomitant NSAID therapy
• To prevent bleeding from hypertensive gastropathy in cirrhotic patients
• Acute pancreatitis
• Stress ulcer prophylaxis in non-critically ill hospitalized patients that are not at high-risk
for ulcer formation and GI bleeding
PPI use of uncertain benefit • PPI non-responsive GERD
• Extra-digestive GERD
aFDA approved indications
bRequires 3–4 times the usual dose (PPI therapy is typically started as single dose)
cIn these cases, a PPI taper should be attempted to the lowest effective dose, on demand dosing, or intermittent dosing
dIn this case, a 1 to 2 week course of PPI therapy for H. pylori eradication in conjunction with antibiotics is appropriate
GERD gastroesophageal reflux disease, GI gastrointestinal, NSAID non-steroidal anti-inflammatory drugs
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refractory GERD as a cause of their symptoms or to
justify PPI discontinuation. Based on personal experi-
ence, the appropriate intervention is often PPI discon-
tinuation in patients with isolated extra-esophageal
symptoms that have not responded to a PPI trial. Con-
tinuing PPI therapy in such circumstances provides no
benefit and simply exposes patients to the risk of ther-
apy, the other focus to the Scarpignato review [3].
The list of safety concerns related to long-term PPI
use is growing, both in number and in public visibility.
Although largely based on low quality data and, in many
instances, refuted by higher quality data, the warnings
are out there on the TV, the internet, and the package
inserts. This has resulted in widespread PPI angst among
patients and not a day goes by that this is not the topic
of a patient consultation in a specialty gastrointestinal
disorders practice. Scarpignato et al. [3] comprehensively
review both the digestive and extra-digestive concerns
about PPI usage, but ultimately reiterate that PPIs are
well tolerated and that the benefits of PPI treatment out-
weigh potential risks when PPIs are used for an appro-
priate indication. Table 2 summarizes available safety
information on long-term PPI use with the concerns
grouped by the strength of substantiating data and sig-
nificance. Evident in the table, there is little there of
sufficient concern to alter practice, providing that PPI
use is appropriate.
Conclusions
In summary, Scarpignato et al. [3] should be com-
mended for this remarkable effort. In addition to the
major points detailed above, there are numerous
pearls pertinent to comparative PPI pharmacology
and metabolism contained within the text. However,
the overwhelming message is that the problem with
PPIs is that they are good, very good. Consequently,
there are a lot of valid indications for their use. How-
ever, clinicians cannot be complacent, thinking that
the overwhelming efficacy of the drugs in the treat-
ment of peptic esophagitis and ulcer disease will be
matched in all other putative applications. Decisions
to start, properly dose, continue, or discontinue PPI
therapy should be personalized based on indication,
effectiveness, patient preferences, and risk assessment.
Guidelines are important, but they should not be in-
flexible. Clinicians need flexibility to tailor therapy to
specific patient circumstances and experience. Only
then does one achieve the optimal balance between
risk and benefit.
Table 2 Quality of evidence and risks of adverse effects associated with long-term proton pump inhibitors (PPIs)
Potential adverse effect Nature of evidence Risk estimate
Causality established, idiosyncratic,
rare
Acute interstitial nephritis Observational, case–control OR 5.16 (2.21–12.05)
Causality proven but of minimal
significance
Fundic gland polyps Observational OR 2.2 (1.3–3.8) [6]
B12 deficiency Observational, case–control OR 1.65 (1.58–1.73) [7]
Weak association, causality
probable
Small intestinal bacterial overgrowth Meta-analysis OR 2.28 (1.23–4.21) [8]
Spontaneous bacterial peritonitis
in cirrhotic patients
Systematic review/meta-analysis OR 2.17 (1.46–3.23) [9]
Hepatic encephalopathy in
cirrhotic patients
Observational, case–control Dose dependent response,
up to OR 3.01 (1.78–5.10) [10]
Clostridium difficile infection Observational cohort study OR 2.10 (1.20–3.50)
Iron deficiency Observational, case control OR 2.49 (2.35–2.64) [11]
Hypomagnesemia Observational, population-based cohort OR 2.00 (1.36–2.93)a [12]
Weak association, unproven
causality
Bone fracture Observational, case–control OR 2.65 (1.80–3.90)
Chronic kidney disease Observational, population-
based cohort




Myocardial infarction Observational, data mining HR 1.16 (1.09–1.24)b
Community-acquired pneumonia Systematic review/meta-analysis OR 1.49 (1.16–1.92)b
Table adapted from Kia et al. [14]
aThe risk of hypomagnesemia increases to OR 7.22 (1.69–30.83) in patients on concurrent loop diuretics
bRisk ratio based on observational study; no association found in RCTs
HR hazard ratio, OR odds ratio
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